Search Results - "Demoret, Bryce"

Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma by Seligson, Nathan D., Stets, Colin W., Demoret, Bryce W., Awasthi, Achal, Grosenbacher, Nicholas, Shakya, Reena, Hays, John L., Chen, James L.

“…Dedifferentiated liposarcoma (DDLPS) is a highly morbid mesenchymal tumor characterized and driven by genomic amplification of the MDM2 gene. Direct inhibition…”
Get full text

Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma by Bill, Kate Lynn J., Seligson, Nathan D., Hays, John L., Awasthi, Achal, Demoret, Bryce, Stets, Colin W., Duggan, Megan C., Bupathi, Manojkumar, Brock, Guy N., Millis, Sherri Z., Shakya, Reena, Timmers, Cynthia D., Wakely, Paul E., Pollock, Raphael E., Chen, James L.

“…Background Dedifferentiated liposarcomas (DDLPS) are mesenchymal tumors associated with universally poor response to treatment. Genomic amplification of murine…”
Get full text

Cutaneous Squamous Cell Carcinoma Arising Within a Previously Irradiated Mycosis Fungoides Lesion by South, Shannon C, Kluglein, Kimberly A, Demoret, Bryce, Miller, Richard

Get full text

Abstract 3529: Modulation of MDM2 alters the metabolomic programming of dedifferentiated liposarcoma and its sensitivity to cholesterol inhibition by Demoret, Bryce, Patt, Andrew, Hays, John, Mathé, Ewy, Chen, James L.

“…BACKGROUND: Dedifferentiated liposarcoma (DDLPS) is a highly morbid, mesenchymal tumor characterized by amplification of the 12q chromosomal loci. Although…”
Get full text

Genomic amplification of CDK4 in dedifferentiated liposarcomas as a predictive biomarker for microtubule disrupting agents by Demoret, Bryce, Rogers, Andrew, Seligson, Nathan David, Kautto, Esko Antero, Hays, John L., Chen, James Lin

“…Abstract only…”
Get full text

Identification of histone deacetylase 2 (HDAC2) as a novel target for MDM2 directed therapies in dedifferentiated liposarcoma by Stets, Colin W, Demoret, Bryce, Grosenbacher, Nicholas, Hays, John L., Chen, James Lin

“…Abstract only…”
Get full text

Exploring ceramide metabolism as a potential target in dedifferentiated liposarcoma by Demoret, Bryce, Patt, Andrew, Stets, Colin W, Hoang, Mindy, Hays, John L., Mathe, Ewy, Chen, James Lin

“…Abstract only e22558 Background: Dedifferentiated liposarcomas (DDLPS) are highly aggressive mesenchymal tumors characterized by MDM2 amplification. Elevated…”
Get full text

Prospective Evaluation of the Concordance of Commercial Circulating Tumor DNA Alterations with Tumor-Based Sequencing across Multiple Soft Tissue Sarcoma Subtypes by Demoret, Bryce, Gregg, Jeff, Liebner, David A, Tinoco, Gabriel, Lenobel, Scott, Chen, James L

“…Soft tissue sarcomas (STS) are diverse tumors with heterogenous alterations. Platforms to detect circulating tumor DNA (ctDNA) have rapidly increased in…”
Get full text

MDM2-Dependent Rewiring of Metabolomic and Lipidomic Profiles in Dedifferentiated Liposarcoma Models by Patt, Andrew, Demoret, Bryce, Stets, Colin, Bill, Kate-Lynn, Smith, Philip, Vijay, Anitha, Patterson, Andrew, Hays, John, Hoang, Mindy, Chen, James L., Mathé, Ewy A.

“…Dedifferentiated liposarcoma (DDLPS) is an aggressive mesenchymal cancer marked by amplification of MDM2, an inhibitor of the tumor suppressor TP53. DDLPS…”
Get full text

Loss of TXNIP enhances peritoneal metastasis and can be abrogated by dual TORC1/2 inhibition by Spaeth-Cook, Douglas, Burch, Mark, Belton, Robin, Demoret, Bryce, Grosenbacher, Nicholas, David, Jason, Stets, Colin, Cohen, David, Shakya, Reena, Hays, John L, Chen, James L

“…Peritoneal metastasis (PM) is a debilitating consequence of multiple cancers. As cancer cells lose tonic signaling related to attachment dependence, critical…”
Get full text